We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+2.7%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$415M
AUM Growth
+$35.8M
Cap. Flow
+$32.9M
Cap. Flow %
7.93%
Top 10 Hldgs %
52.35%
Holding
76
New
10
Increased
22
Reduced
9
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$15.5M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$13.1M
3
ILMN icon
Illumina
ILMN
+$12.8M
4
INCY icon
Incyte
INCY
+$10.1M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$7.79M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.3M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.9M
3
UTHR icon
United Therapeutics
UTHR
+$7.77M
4
XLRN
Acceleron Pharma
XLRN
+$7.59M
5
BIIB icon
Biogen
BIIB
+$7.54M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLRN
76
DELISTED
Acceleron Pharma
XLRN
– –
-60,500
Closed -$7.59M
1 2 3
4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q3 2021 Portfolio in Review

As of Q3 2021, International Biotechnology Trust held 76 positions worth $415M, up 9.5% from $379M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

International Biotechnology Trust deployed $32.9M of net new capital in Q3 2021, opening 10 new positions and adding to 22 existing holdings. Its largest new stake was Illumina: 27,756 shares worth $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $18.3M trimmed.

  • International Biotechnology Trust's largest Q3 2021 buy was Illumina: 27,756 shares worth $10.9M.
  • International Biotechnology Trust added most to Amgen in Q3 2021, an estimated $15.5M increase.
  • International Biotechnology Trust's biggest Q3 2021 reduction was Regeneron Pharmaceuticals, cutting an estimated $18.3M.
  • International Biotechnology Trust fully exited United Therapeutics in Q3 2021, selling an estimated $7.77M.
  • International Biotechnology Trust's ten largest holdings make up 52% of its $415M portfolio in Q3 2021.
  • International Biotechnology Trust opened 10 new positions and closed 8 in Q3 2021.
  • International Biotechnology Trust's portfolio value rose 9.5% quarter-over-quarter to $415M.

Based on International Biotechnology Trust's 13F filing for Q3 2021, filed 12 Nov 2021.